NAV

Guanoxan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Guanoxan
DrugBank Accession Number
DB13211
Background

Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 207.233
Monoisotopic: 207.100776671
Chemical Formula
C10H13N3O2
Synonyms
  • Guanoxan
  • Guanoxano
  • Guanoxanum
External IDs
  • BRN 1251616
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbaloparatideAbaloparatide may increase the hypotensive activities of Guanoxan.
AcebutololAcebutolol may increase the hypotensive activities of Guanoxan.
AceclofenacThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Guanoxan.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Guanoxan sulfateN6IT80R85G5714-04-5NSGHAKPGHCNTPS-UHFFFAOYSA-N

Categories

ATC Codes
C02CC03 — Guanoxan
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzo-1,4-dioxanes. These are heterocyclic compounds containing a benzene ring fused to a 1,4-dioxane ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxanes
Sub Class
Benzo-1,4-dioxanes
Direct Parent
Benzo-1,4-dioxanes
Alternative Parents
Alkyl aryl ethers / Para dioxins / Benzenoids / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Carboximidamides / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkyl aryl ether / Aromatic heteropolycyclic compound / Benzenoid / Benzo-1,4-dioxane / Carboximidamide / Ether / Guanidine / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9V0MRL0R5Y
CAS number
2165-19-7
InChI Key
HIUVKVDQFXDZHU-UHFFFAOYSA-N
InChI
InChI=1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)
IUPAC Name
N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]guanidine
SMILES
NC(=N)NCC1COC2=C(O1)C=CC=C2

References

General References
Not Available
ChemSpider
15704
ChEBI
134871
ChEMBL
CHEMBL76725
Wikipedia
Guanoxan

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.33 mg/mLALOGPS
logP0.1ALOGPS
logP0.42Chemaxon
logS-2.2ALOGPS
pKa (Strongest Basic)11.99Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area80.36 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity65.35 m3·mol-1Chemaxon
Polarizability21.58 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0290000000-f2d57aed3782fbae2af4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9200000000-4749ed4b8bd4e68f4231
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-052e-6910000000-187a7f83612d585ffd80
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-caf4864e3e0d06f77883
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-61a8aa41988beb4a97bd
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-db9827e602adb8258ae7
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-140.53322
predicted
DeepCCS 1.0 (2019)
[M+H]+143.96153
predicted
DeepCCS 1.0 (2019)
[M+Na]+153.02455
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:37 / Updated at February 21, 2021 18:54